Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall S.A.filedCriticalAlmirall S.A.
Publication of RS51924BpublicationCriticalpatent/RS51924B/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
NOVE METODE. Aclidinium za upotrebu u lečenju ili sprečavanju neke respiratorne bolesti ili stanja kod pacijenta putem inhalacije, pri čemu pacijent boluje ili je podložan stanju koje može biti pogoršano sistemskom antimuskarinskom aktivnošću.Prijava sadrži još 12 patentnih zahteva.NEW METHODS. Aclidinium for use in the treatment or prevention of a respiratory disease or condition in a patient by inhalation, wherein the patient is ill or susceptible to a condition that may be exacerbated by systemic antimuscarinic activity. The application contains 12 additional claims.
1-?á2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL?åPIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION